Changes of hemostatic factors in patients with hemoglobinopathies

Turkish Journal of Pediatrics

Volumn 41, Issue 3, 1999, Pages 323-327

  Öner, Ahmet Faik ^a   Gürgey, Aytemiz ^a   Okur, Hamza ^a   Kirazli, Şerafettin ^a   Gümrük, Fatma ^a   Altay, Çiǧdem ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Activation in coagulation; Coagulation inhibitors; Sickle cell disease; Thalassemia

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING INHIBITOR;

ADOLESCENT; ARTICLE; BETA THALASSEMIA; BLOOD; FEMALE; HUMAN; MALE; SICKLE CELL ANEMIA;

ADOLESCENT; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; FEMALE; HUMANS; MALE;

EID: 0033156441     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Sinniah D, Vignaendra V, Kamaruddin A. Neurological complications of β-thalassemia major. Arch Dis Child 1977; 52: 977-979.
2. Kale N, Hiçsönmez G, Gürgey A, Kale G, Altay Ç. Splenektomi sonrasi mezenter damar trombozu gelişen bir talessemia intermedia vakasi. Çocuk Saǧliǧi ve Hastaliklari Dergisi 1986; 29: 67-70.
3. Karayalçin G, Lanzkowsky P. Plasma protein C levels in children with sickle cell disease. Am J Pediatr Hematol Oncol 1989; 11: 320-323.
4. Hagger D, Wolff S, Owen J, Samson D. Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrin 1995; 6: 93-99.
5. Green D, Scott JP. Is sickle cell crisis a thrombotic event? Am J Hematol 1986; 23: 317-321.
6. Helley D, Girot R, Guillin MC, Bezeaurd A. Sickle cell disease: relation between procoagulant activity of red blood cells from different phenotypes and in-vivo blood coagulation activation. Br J Haematol 1997; 99: 268-272.
7. Altay Ç, Gürgey A. β-thalassemia in Turkey. Hematol Reviews 1992; 6: 17-81.
8. Bick LB. Hypercoagulability and thrombosis. In: Bick RL (ed). Common Bleeding and Clotting Disorders for the Internist. Med Clin North Am 1994; 78: 635-665.
9. Peters BE, ten Cate H, Wolters HJ, Weening RS, Brandjes DP. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 1994; 71: 169-172.
10. Toulon P, Vitoux JF, Fiessenger JN, et al. Heparin cofactor II: an acute phase reactant in patients with deep vein thrombosis. Blood Coagul Fibrinolysis 1991; 3: 435-439.
11. Driscol A, Mackie IJ, Porter B, Machin SJ. Low plasma heparin cofactor II levels in thalassemia syndromes are corrected by chronic blood transfusion. Br J Haematol 1995; 90: 65-70.
12. Rinder MR, Richard RE, Rinder HM. Acquired von Willebrand disease: a concise reiew. Am J Hematol 1997; 54: 139-145.